Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial

医学 安慰剂 益生菌 内科学 泌尿系统 安慰剂对照研究 抗生素 不利影响 胃肠病学 随机对照试验 临床试验 双盲 微生物学 细菌 病理 生物 替代医学 遗传学
作者
Varsha Gupta,Paola Mastromarino,Ritu Garg
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:78 (5): 1154-1161 被引量:4
标识
DOI:10.1093/cid/ciad766
摘要

Abstract Background Widespread antibiotic resistance has sparked interest in the identification of nonantibiotic strategies, particularly probiotics for the prevention of recurrent urinary tract infections (UTIs). We evaluated the effectiveness of prophylactic probiotic supplementation through oral and intravaginal routes in the prevention of recurrent UTIs. Methods This double-blind, placebo-controlled study enrolled 174 premenopausal women with a history of recurrent UTIs and randomized them to 1 of the 4 treatment groups: placebo (G1, oral placebo + vaginal placebo), oral probiotic (G2, oral lactic acid bacteria and bifidobacteria + vaginal placebo), vaginal probiotic (G3, oral placebo + vaginal lactobacilli), and probiotic combination (oral lactic acid bacteria and bifidobacteria + vaginal lactobacilli), for 4 months. Participants were followed up for symptomatic UTIs for 1 year. The primary end points were the number of symptomatic UTIs at 4 months, the proportion of participants with at least 1 symptomatic UTI, and the time to the first symptomatic UTI. Results The incidence of UTI at 4 months in G1, G2, G3, and G4 was 70.4%, 61.3%, 40.9%, and 31.8%, respectively. The mean number of symptomatic UTI recurrences at 4 months was significantly lower (P < .05) in G3 (1.06) and G4 (1.07) compared with G1 (2.1) and G2 (1.63). Further, the time to first symptomatic UTI (days) was significantly longer (P < .05) in G3 (123.8) and G4 (141.8) compared with G1 (69.3) and G2 (71.9). Probiotic supplementations were well tolerated with no serious adverse events. Conclusions Prophylactic supplementation with either vaginal probiotics or in combination with oral probiotics demonstrated effectiveness in preventing recurrent symptomatic UTI episodes. Clinical Trials Registration Registered at Clinical Trials Registry India (CTRI): CTRI/2014/02/004425 (https://ctri.nic.in).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
clovers完成签到,获得积分10
1秒前
皇帝的床帘应助英俊丹秋采纳,获得30
1秒前
yang发布了新的文献求助30
2秒前
万能图书馆应助努力学习采纳,获得10
2秒前
4秒前
5秒前
香蕉觅云应助CR7采纳,获得10
5秒前
贪玩香芦完成签到,获得积分10
9秒前
xuhan应助Meihi_Uesugi采纳,获得20
9秒前
恰逢其时而已完成签到 ,获得积分10
10秒前
听白发布了新的文献求助10
10秒前
11秒前
思源应助wanci采纳,获得10
13秒前
WZJ发布了新的文献求助10
14秒前
LYY发布了新的文献求助10
14秒前
14秒前
Fisher发布了新的文献求助10
15秒前
16秒前
xiaofei666应助韵竹采纳,获得30
16秒前
hswhswqkdh应助俏皮的映易采纳,获得10
17秒前
18秒前
菲菲菲菲完成签到,获得积分10
18秒前
bkagyin应助优美语风采纳,获得10
18秒前
子车茗应助殷启维采纳,获得10
19秒前
吡啶应助贪玩香芦采纳,获得10
19秒前
菲菲菲菲发布了新的文献求助10
21秒前
21秒前
乐多发布了新的文献求助10
22秒前
斯文败类应助小青采纳,获得10
22秒前
23秒前
Fisher完成签到,获得积分10
23秒前
26秒前
王大壮完成签到,获得积分10
26秒前
orixero应助菲菲菲菲采纳,获得10
26秒前
萧羽完成签到,获得积分10
26秒前
27秒前
27秒前
玉桂兔完成签到,获得积分10
28秒前
lxy发布了新的文献求助10
30秒前
香蕉觅云应助gemini0615采纳,获得10
30秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3160894
求助须知:如何正确求助?哪些是违规求助? 2812133
关于积分的说明 7894461
捐赠科研通 2470993
什么是DOI,文献DOI怎么找? 1315830
科研通“疑难数据库(出版商)”最低求助积分说明 631036
版权声明 602068